220 related articles for article (PubMed ID: 24136187)
21. Combination 5-alpha-reductase inhibitors and alpha-blockers for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Clarke JC; Clarke H
Curr Urol Rep; 2008 Jul; 9(4):291-4. PubMed ID: 18765128
[TBL] [Abstract][Full Text] [Related]
22. 5-Alpha-Reductase Inhibitors and Combination Therapy.
Füllhase C; Schneider MP
Urol Clin North Am; 2016 Aug; 43(3):325-36. PubMed ID: 27476125
[TBL] [Abstract][Full Text] [Related]
23. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk.
Emberton M; Zinner N; Michel MC; Gittelman M; Chung MK; Madersbacher S
BJU Int; 2007 Aug; 100(2):249-53. PubMed ID: 17617135
[TBL] [Abstract][Full Text] [Related]
24. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
Naslund M; Eaddy MT; Hogue SL; Kruep EJ; Shah MB
Curr Med Res Opin; 2009 Nov; 25(11):2663-9. PubMed ID: 19757985
[TBL] [Abstract][Full Text] [Related]
25. Change in International Prostate Symptom storage subscore after long-term medical therapy in BPH patients: finasteride and alpha-blocker combination therapy in men with moderate-to-severe LUTS/BPH in Korea.
Lee JY; Lee SH; Kim SJ; Kim CS; Lee HM; Kim CI; Chung BH
Urology; 2011 Jan; 77(1):171-6. PubMed ID: 20691464
[TBL] [Abstract][Full Text] [Related]
26. [Pharmacological treatment of benign prostatic hyperplasia].
Oelke M; Martinelli E
Urologe A; 2016 Jan; 55(1):81-94; quiz 95-6. PubMed ID: 26676726
[TBL] [Abstract][Full Text] [Related]
27. Clinical outcomes of withdrawing one medication from long-term combination therapy comprising α-blocker and 5α-reductase inhibitor for benign prostatic hyperplasia.
Choi JD; Yoo TK; Kang JY; Jung HD; Lee JH
Int Urol Nephrol; 2023 Apr; 55(4):845-851. PubMed ID: 36763223
[TBL] [Abstract][Full Text] [Related]
28. Benign Prostatic Hyperplasia - An economic assessment of fixed combination therapy based on a literature review.
Messina R; Mirone V
Arch Ital Urol Androl; 2015 Sep; 87(3):185-9. PubMed ID: 26428637
[TBL] [Abstract][Full Text] [Related]
29. A multiinstitutional study of the effects of medical therapy for lower urinary symptoms on the perioperative outcomes of holmium laser enucleation of the prostate.
Warner JN; Nunez RN; Tyson MD; Viprakasit DP; Miller NL; Humphreys MR
Urology; 2011 Dec; 78(6):1385-90. PubMed ID: 21871654
[TBL] [Abstract][Full Text] [Related]
30. The Impact of Combination Therapy with a-Blockers and 5ARIs on the Progression of BPH.
Sountoulides P; Gravas S
Curr Drug Targets; 2015; 16(11):1172-9. PubMed ID: 25706255
[TBL] [Abstract][Full Text] [Related]
31. Benign Prostatic Hyperplasia.
Langan RC
Prim Care; 2019 Jun; 46(2):223-232. PubMed ID: 31030823
[TBL] [Abstract][Full Text] [Related]
32. [Current role for combination therapy in male LUTS. Editorial comment].
Carballido Rodríguez J
Arch Esp Urol; 2010 Jun; 63(5):333-4. PubMed ID: 21149911
[No Abstract] [Full Text] [Related]
33. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
Pattanaik S; Mavuduru RS; Panda A; Mathew JL; Agarwal MM; Hwang EC; Lyon JA; Singh SK; Mandal AK
BJU Int; 2019 Jul; 124(1):27-34. PubMed ID: 30681264
[TBL] [Abstract][Full Text] [Related]
34. Risk of Incident Antidepressant-Treated Depression Associated with Use of 5α-Reductase Inhibitors Compared with Use of α-Blockers in Men with Benign Prostatic Hyperplasia: A Population-Based Study Using the Clinical Practice Research Datalink.
Hagberg KW; Divan HA; Nickel JC; Jick SS
Pharmacotherapy; 2017 May; 37(5):517-527. PubMed ID: 28295443
[TBL] [Abstract][Full Text] [Related]
35. Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH.
Gravas S; Oelke M
World J Urol; 2010 Feb; 28(1):9-15. PubMed ID: 19956956
[TBL] [Abstract][Full Text] [Related]
36. The effect of alpha-blocker and 5alpha-reductase inhibitor intake on sexual health in men with lower urinary tract symptoms.
Barqawi AB; Myers JB; O'Donnell C; Crawford ED
BJU Int; 2007 Oct; 100(4):853-7. PubMed ID: 17662074
[TBL] [Abstract][Full Text] [Related]
37. Medical therapy for benign prostatic hyperplasia: a review.
Van Asseldonk B; Barkin J; Elterman DS
Can J Urol; 2015 Oct; 22 Suppl 1():7-17. PubMed ID: 26497339
[TBL] [Abstract][Full Text] [Related]
38. Alpha blocker monotherapy versus combination therapy with antimuscarinics in men with persistent LUTS refractory to alpha-adrenergic treatment: patterns of persistence.
Barkin J; Diles D; Franks B; Berner T
Can J Urol; 2015 Aug; 22(4):7914-23. PubMed ID: 26267031
[TBL] [Abstract][Full Text] [Related]
39. Impact of 5α-reductase inhibitor and α-blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality.
Van Rompay MI; Curtis Nickel J; Ranganathan G; Kantoff PW; Solomon KR; Lund JL; McKinlay JB
BJU Int; 2019 Mar; 123(3):511-518. PubMed ID: 30216624
[TBL] [Abstract][Full Text] [Related]
40. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
